Type 1 Diabetes Drug "Teplizumab" Successful in Clinical Trial
August 8, 2013 2:39 PM
comment(s) - last by
It's mainly for pre-diabetics who don't have an advanced version of the disease
A new drug could give pre-diabetics the chance to combat the onset of full-blown
type 1 diabetes
The drug is called teplizumab, and it helped pre-diabetics maintain their current level of insulin production for two full years without the condition worsening. The drug seemed to be most beneficial for pre-diabetics rather than those with advanced type 1 diabetes.
The drug was developed by Jeffrey Bluestone, PhD, an immunologist at UC San Francisco, and Mary Clausen, Distinguished Professor at UC San Francisco. The clinical trial was led by Kevan Herold, MD, PhD, a professor of immunobiology and deputy director for translational science at Yale University.
Teplizumab works by using an antibody targeted against a molecule called CD3. The antibody binds to the immune system's T-cells and stops them from attacking beta cells. This is effective because the disease is caused by the body's immune system destroying insulin-producing beta cells in the pancreas.
"The benefits of treatment among the patients who still had moderately healthy insulin production suggests that the sooner we can detect the pre-diabetes condition and get this kind of drug onboard, the more people we can protect from the progressive damage caused by an autoimmune attack," said Bluestone.
Those who have advanced type 1 diabetes, however, didn't seem to benefit in the clinical trial. Some even lost half or more of their ability to produce insulin, which was likely due to differences in the "metabolic condition of the patients and in the severity of their disease."
For those who are past the point of pre-diabetes, don't fret. Just earlier this year, researchers from the Universitat Autònoma de Barcelona significantly improved the
blood glucose levels
of dogs with type 1 diabetes through a gene therapy that consists of a single session of multiple injections. These injections presented adeno-associated vectors (AAV) that both expressed the insulin gene, and also glucokinase (an enzyme that regulates an uptake of glucose from the blood). When both genes were expressed, the excess of blood sugar in type 1 diabetic dogs was controlled over a long-term period.
This article is over a month old, voting and posting comments is disabled
RE: Makes sense
8/9/2013 12:32:11 AM
Wonder what, or if, the side effects are?
RE: Makes sense
8/9/2013 8:44:12 AM
shouldn't it be obvious what the side effects are?
"My sex life is pretty good" -- Steve Jobs' random musings during the 2010 D8 conference
Gene Therapy Controls, Cures Type 1 Diabetes in Dogs
February 11, 2013, 1:59 PM
Artificial Pancreas Improves Glucose Control by 15%, Benefits Type 1 Diabetes Patients
January 30, 2013, 5:55 PM
Creationists are Mad About Google Doodle Depicting Evolution
November 24, 2015, 8:48 PM
DHS and TSA: Whoops, We Missed That 73 Airport Employees May be Terrorists
November 19, 2015, 2:16 PM
Star Wars Spinoff Film "Rogue One", Theme Park Attractions Announced
August 17, 2015, 12:20 PM
SpaceX Falcon 9's Seventh Supply Mission to ISS Ends w/ Fiery Stage 1 Explosion
June 28, 2015, 1:10 PM
Cool Science Video: Glowing Millipede Prowls the Nevada Desert
May 18, 2015, 12:00 PM
Newly Discovered Costa Rican Glass Frog is Kermit's Doppelgänger
April 22, 2015, 11:26 AM
Latest Blog Posts
Sceptre Airs 27", 120 Hz. 1080p Monitor/HDTV w/ 5 ms Response Time for $220
Dec 3, 2014, 10:32 PM
Costco Gives Employees Thanksgiving Off; Wal-Mart Leads "Black Thursday" Charge
Oct 29, 2014, 9:57 PM
"Bear Selfies" Fad Could Turn Deadly, Warn Nevada Wildlife Officials
Oct 28, 2014, 12:00 PM
The Surface Mini That Was Never Released Gets "Hands On" Treatment
Sep 26, 2014, 8:22 AM
ISIS Imposes Ban on Teaching Evolution in Iraq
Sep 17, 2014, 5:22 PM
More Blog Posts
Copyright 2016 DailyTech LLC. -
Terms, Conditions & Privacy Information